Collapse all
The Business Model Canvas reveals a high-value, specialized clinical service that shifts psychiatric care from chronic daily medication to an episodic, high-impact intervention. Success depends on navigating strict regulatory environments and securing partnerships with prestige medical institutions to validate the rapid-response protocol.
4 Academic Medical Centers Partnerships with institutions like the Mayo Clinic to provide clinical credibility and a pipeline of TRD patients. Pharmaceutical Manufacturers Suppliers of synthetic, pharmaceutical-grade psilocybin to ensure dosage consistency and regulatory compliance. Regulatory Bodies (FDA/DEA) Essential for obtaining the necessary licenses to administer Schedule I substances in a clinical setting. Health Insurance Providers Collaborators to establish reimbursement codes for a high-cost, single-intervention model versus chronic prescriptions. 4 Clinical Protocol Execution Administering the 25mg psilocybin dose alongside structured psychological support and monitoring. Patient Screening Identifying patients who specifically meet the 'treatment-resistant' criteria and fail standard SSRIs. Outcome Tracking Measuring MADRS score reductions and functional disability improvements to prove efficacy to payers. Therapeutic Integration Providing the psychological support necessary to translate the psychedelic experience into long-term remission. 4 Specialized Clinical Staff Psychiatrists and trained facilitators capable of managing high-dose psychedelic sessions. Certified Treatment Facilities Secure, therapeutic environments designed for the safety and comfort of patients during the experience. Clinical Evidence Base Proprietary data and research evidence showing the 57% remission rate compared to escitalopram. Regulatory Licenses Legal permits required to handle and administer controlled substances. 4 Rapid Symptom Reduction Offering a fast alternative to the slow onset of SSRIs for patients in acute TRD episodes. Higher Remission Probability Providing a pathway with a significantly higher remission rate (57%) than traditional antidepressants (28%). Reduced Medication Burden Moving patients from daily chemical dependency to a short-course or single-dose intervention. Functional Recovery Focusing on the sustained reduction of functional disability rather than just symptom management. 3 High-Touch Clinical Care Intensive, personalized support during the dosing and integration phases. Referral-Based Trust Building deep trust with referring psychiatrists who manage TRD patients. Patient Support Groups Creating communities for those who have transitioned from SSRIs to the rapid-response protocol. 3 Specialist Referrals Direct pipelines from psychiatric clinics and primary care physicians treating MDD. Medical Partnerships Integration into the patient pathways of large health systems like the Mayo Clinic. Clinical Trial Networks Attracting patients through research-led recruitment for treatment-resistant populations. 3 TRD Patients Adults with moderate-to-severe Major Depressive Disorder who have failed multiple standard SSRI treatments. Health Systems Institutions like the Mayo Clinic seeking to offer cutting-edge, evidence-based psychiatric interventions. Insurance Payers Providers interested in reducing the long-term cost of chronic depression management through rapid remission. 4 Specialized Labor High costs for trained psychiatric facilitators and medical monitors. Facility Overhead Maintenance of specialized, safe, and compliant clinical environments. Regulatory Compliance Ongoing costs for legal auditing, DEA compliance, and safety monitoring. Drug Procurement Costs associated with sourcing pharmaceutical-grade synthetic psilocybin. 3 Per-Protocol Fee A high-ticket flat fee for the full rapid-response package (screening, dosing, and integration). Insurance Reimbursement Payment per episode of care based on negotiated rates for TRD specialized treatment. Follow-up Care Subscriptions Recurring fees for long-term monitoring and maintenance of remission status. The idea identifies specific beneficiaries like Mayo Clinic and insurance providers, making it necessary to map out the value delivery and reimbursement model. · Generated 2026-09-05 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated